Announcements
European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with S.O.G.
Original Research
Expression of beclin 1, an autophagy-related protein, in human cervical carcinoma and its clinical significance
Show Less
1
Department of Obstetrics and Gynecology, Qingdao Central Hospital, Qingdao, Shandong
2
Department of Gynecology, Cancer Center, Sun Yat-Sen University, Guangzhou, Guangdong
3
Department of Pathology, Cancer Center, Sun Yat-Sen University, Guangzhou, Guangdong (P. R. China)
Eur. J. Gynaecol. Oncol. 2012, 33(1), 15–20;
Published: 10 February 2012
Abstract
Purpose: To investigate the impact of beclin 1 on prognosis of cervical cancer, we determined the expression of beclin 1 in cervical cancer, cervical intraepithelial neoplasia (CIN) and normal cervical tissues. Methods: A total of 122 cases of cervical cancer, 35 cases with CIN and 31 cases with uterine fibroids were collected at the Cancer Center of Sun Yat University to determine the expression of beclin 1. Results: Beclin 1 positive rate in normal cervical tissues, CIN tissues and cervical cancers was 83.9%, 74.3% and 53.3%, respectively, and it was significantly different between the three groups (p < 0.01). Beclin 1 expression was negatively correlated with cervical cancer differentiation, lymph node metastasis, recurrence and death (p < 0.05). The negative expression is the risk factor affecting overall survival (p < 0.05) and progression-free survival (PFS) (p < 0.05). Multivariate analysis showed that beclin 1 negative expression was an independent risk factor of PFS time. Conclusions: Beclin 1 may play a role in the occurrence and development of cervical cancer. Beclin 1 positive expression in patients indicates a better prognosis.
Keywords
Cervical cancer
Autophagy
Beclin 1
Overall survival (OS)
Progression-free survival (PFS)
Share
Back to top